Safety and efficacy of repeated monthly carboplatin desensitization

Morgan, Matt; Bowers, Daniel C.; Gruchalla, Rebecca S.; Khan, David A.

doi:10.1016/j.jaci.2004.05.061

Cited by 18 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chang et al were not able to continue carboplatin in any of five CHR patients with premedication [7] (Table 5). There are some case reports pointing at the success of desensitization protocol in childhood CHR [4,21]. However, the number of patients was not sufficient for one to make a conclusion in terms of efficacy.…”

Section: Discussionmentioning

confidence: 99%

Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma

Genc

Canpolat

Berrak

2011

Support Care Cancer

View full text Add to dashboard Cite

This is the largest single-center study conducted to investigate the frequency and the management strategies in patients with CHR who were treated with the same chemotherapy protocol for LGG. Premedication and desensitization were the preferred modifications in case of CHR. Overall, the success rate for carboplatin continuation is high in comparison to previous studies. Carboplatin can be continued successfully in many cases with CHR if reactions are managed in a timely fashion.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma

Genc

Canpolat

Berrak

2011

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…These results are in agreement with previous publications, most of them including only case reports. [3][4][5]17 Two studies reported small groups of patients that were desensitized successfully. Markman et al 11 reported successful desensitization in four of five patients with either a hypersensitivity reaction or a positive skin test to carboplatin.…”

Section: Discussionmentioning

confidence: 99%

Successful carboplatin desensitization in patients with proven carboplatin allergy

Confino‐Cohen

Fishman

Altaras

et al. 2005

Cancer

View full text Add to dashboard Cite

We present the first all‐atom model for the structure of a T = 3 virus, pariacoto virus (PaV), which is a nonenveloped, icosahedral RNA virus and a member of the Nodaviridae family. The model is an extension of the crystal structure, which reveals about 88% of the protein structure but only about 35% of the RNA structure. New modeling methods, combining coarse‐grained and all‐atom approaches, were required for developing the model. Evaluation of alternative models confirms our earlier observation that the polycationic N‐ and C‐terminal tails of the capsid proteins must penetrate deeply into the core of the virus, where they stabilize the structure by neutralizing a substantial fraction of the RNA charge. This leads us to propose a model for the assembly of small icosahedral RNA viruses: nonspecific binding of the protein tails to the RNA leads to a collapse of the complex, in a fashion reminiscent of DNA condensation. The globular protein domains are excluded from the condensed phase but are tethered to it, so they accumulate in a shell around the condensed phase, where their concentration is high enough to trigger oligomerization and formation of the mature virus. © 2009 Wiley Periodicals, Inc. Biopolymers 91: 530–538, 2009. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com

show abstract

“…Multiple protocols have been used for the desensitization of patients with carboplatin hypersensitivity reactions [15,25,26] . We performed 162 desensitizations in 54 patients with severe hypersensitivity reactions to platins with the standardized desensitization protocol described in table 1 , the same as for taxene desensitizations with 3 solutions and 12-steps for 5.8 h [20,23] .…”

Section: Rapid Desensitization For Hypersensitivity Reactions To Platinsmentioning

confidence: 99%

Drug Desensitization in Oncology: Chemotherapy Agents and Monoclonal Antibodies

Castells¹

2007

Drug Hypersensitivity

View full text Add to dashboard Cite

The need to offer first-line therapy for primary and recurrent cancers and for treating chronic inflammatory diseases has spurred the clinical development of rapid desensitizations for chemotherapy and monoclonal antibodies. Rapid desensitization allows patients to be treated with medications to which they have presented hypersensitivity reactions, including anaphylaxis. Rapid desensitization induces temporary clinical tolerization and is achieved by administering small incremental doses of the drug inducing the hypersensitivity reaction up to the full therapeutic dose within a few hours. Protocols are available for most chemotherapy agents, including taxenes, platins, doxorubicin, monoclonal antibodies and others. Candidate patients include those who present type I hypersensitivity reactions, mast cell/IgEdependent, including anaphylaxis, during the chemotherapy infusion or shortly after. Anaphylactoid reactions are amenable to treatment with the same rapid desensitization protocols as for type I hypersensitivity reactions. Idiosyncratic reactions and T-cell-mediated reactions are not amenable to rapid desensitization. The indication for rapid desensitization can only be made by allergy and immunology specialists and can only be performed in settings with oneto-one nurse-patient care and where resuscitation personnel and resources are readily available. Repeated desensitizations can be safely performed in outpatient settings with similar conditions, which allows cancer patients to remain in clinical studies and permits the treatment of cancer and chronic rheumatologic and gastrointestinal conditions.

show abstract

Safety and efficacy of repeated monthly carboplatin desensitization

Cited by 18 publications

References 10 publications

Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma

Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma

Successful carboplatin desensitization in patients with proven carboplatin allergy

Drug Desensitization in Oncology: Chemotherapy Agents and Monoclonal Antibodies

Contact Info

Product

Resources

About